Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MyClad phase 3 trial of oral cladribine in generalized myasthenia gravis
2023-507746-83-00Phase 3Authorised
- Sponsor
- Merck KGaA
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 29
01
Overview
Phase 3, randomised, double-blind trial of cladribine in myasthenia gravis (MG) (3 arms), sponsored by Merck KGaA. Primary endpoint: Change from baseline in Myasthenia Gravis - Activities of Daily Living scale score at Week 24. Planned start Nov 2024; status: authorised.
02
Drugs
cladribine
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2023-507746-83-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507746-83-00.